Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events (EKVASIS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Elpen Pharmaceutical Co. Inc.
Sponsor:
Information provided by (Responsible Party):
Elpen Pharmaceutical Co. Inc.
ClinicalTrials.gov Identifier:
NCT01770210
First received: January 14, 2013
Last updated: January 30, 2014
Last verified: May 2013
  Purpose

In western societies hypercholesterolemia is one of the major and independent factors that predispose to cardiovascular disease and death from them. According to the clinical study ATTICA, conducted during the years 2001-2002, in which randomized 1514 men and 1528 women, rates of hypercholesterolemia observed in a sample of urban population was 39% for men and 37% women . The prevalence in the corresponding U.S. epidemiological study NIANES was 52% for men and 49% women. The relationship between cholesterol, lipid-lowering therapy and risk of cardiovascular disease appears to be quite clear in the secondary prevention trials, the 4S (Scandinavian Simvastatin Survival Study), CARE (Cholesterol And Recurrent Events) and LIPID (Long-term Intervention with Pravastatin in Ischemic Disease) which showed the benefits of lowering LDL cholesterol in patients with coronary artery disease. Despite these remarkable results, studies were secondary prevention as a major shortcoming, the lack of patients with acute coronary events. This gap came to cover the study MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering). In MIRACL study , atorvastatin 80 mg was evaluated in 3,086 patients (atorvastatin n = 1.538, placebo n = 1.548), acute coronary syndrome (myocardial infarction without Q-wave or unstable angina). Treatment was initiated during the acute phase after hospital admission and lasted for a period of 16 weeks. Treatment with atorvastatin 80 mg / day increased the latency of the combined primary endpoint, defined as death from any cause, nonfatal myocardial infarction, resuscitated cardiac arrest, or angina with objective evidence of myocardial ischemia requiring admission to hospital, indicating a risk reduction of 16% (p = 0,048). This was mainly due to a 26% reduction in re-hospitalization for angina with objective evidence of myocardial ischemia. The other secondary endpoints were not statistically significant by themselves (total: placebo: 22.2%, Atorvastatin: 22.4%).

Statins by reducing coronary syndromes, it appears that contribute to reducing the incidence of cardiovascular diseases. This is exactly what was observed in 4S, in which the incidence of chronic heart failure (CHF) during follow-up was 10.3% for those who received placebo and 8.3% in the simvastatin group, a finding which translates 19% reduction in heart failure (P <0,015) nationwide with the appearance episode (event) CV.


Condition Intervention
Cardiovascular Disorders
Drug: Patients on atorvastatin treatment

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Multicenter, Open-label, 30-week Observational Clinical Study to Examine the Progress of Patients After Leaving the Cardiology Clinic or Unit Due to Acute Cardiovascular Event.

Resource links provided by NLM:


Further study details as provided by Elpen Pharmaceutical Co. Inc.:

Primary Outcome Measures:
  • Change of lipids (LDL-C, HDL-C, T-CHOL)levels from baseline to the end of the studyCHOL) plasma blood Evaluation of atorvastatin (Antorcin) treatment per study subgroup [ Time Frame: 0 months, 1-1,5 months, 4-4,5 months, 7-7,5 months ] [ Designated as safety issue: Yes ]
    The evaluation of atorvastatin treatment to all patients with cardiovascular events and separate the two subgroups (diabetes type II patients with metabolic syndrome) in order to achieve the level of lipids (LDL-C, HDL-C, T-CHOL) plasma blood

  • Change of LDL-C, HDL-C, T-CHOL from baseline to the end of the study by atorvastatin dosage scheme [ Time Frame: 0 months, 1-1,5 months, 4-4,5 months, 7-7,5 months ] [ Designated as safety issue: Yes ]
    Achieving the level of lipids (LDL-C, HDL-C, T-CHOL) in blood plasma of patients in the atorvastatin dosage: those who received the 40 mg dose and those who received a dose of 80 mg


Secondary Outcome Measures:
  • Measurement of days without treatment - Patients' compliance [ Time Frame: 0 months, 1-1,5 months, 4-4,5 months, 7-7,5 months ] [ Designated as safety issue: No ]
    The investigation of compliance to treatment (days without taking medication, changing the time of intake) and its correlation with the achievement of target lipid levels (LDL-C, HDL-C, T-CHOL) in blood plasma of the studied patients

  • Number of Adverse Events during study duration [ Time Frame: 0 (baseline), 7-7,5 months ] [ Designated as safety issue: Yes ]
    Safety evaluation by adverse events reporting


Other Outcome Measures:
  • Changes in other than lipids hematological and biochemical parameters from baseline until the end of the study [ Time Frame: 0, 1-1,5 months, 4-4,5 months, 7-7,5 months ] [ Designated as safety issue: Yes ]
    The reporting of hematological and biochemical tests where conducted at each hospital center, as part of their standard clinical practice

  • Number of participants per dyslipidemia categorization [ Time Frame: 0 months (baseline) ] [ Designated as safety issue: Yes ]
    The determination of dyslipidemia class it belongs to each patient in order to assess the efficacy of atorvastatin administered.


Estimated Enrollment: 900
Study Start Date: February 2013
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cardiovascular events
Patients on atorvastatin treatment hospitalised due to cardiovascular events
Drug: Patients on atorvastatin treatment
Statins Therapy

  Hide Detailed Description

Detailed Description:

Determination of cardiovascular risk

If the assessment of cardiovascular risk remains incomplete, can identify indicators that measure risk:

  1. Framingham Risk Score: Includes age, sex, total and HDL-CHOL, and levels of blood pressure (can underestimate the risk in some patients).
  2. PROCAM Risk Score: also includes triglycerides, fasting glucose tolerance and family history.
  3. Reynolds Risk Score: Includes family history and levels of hsCRP.
  4. Greek Score (www.hearts.org / greece). People with low risk The Framingham Risk Score shows <10% chance of cardiovascular disease over the next 10 years. Dealing mainly with healthy dietary intervention or drugs when the levels of LDL-CHOL> 190 mg / dL or atherogenic index (T-CHOL/HDL-CHOL)> 6.

Medication is necessary in individuals with familial hypercholesterolemia to reduce the LDL CHOL <100 mg / dL. For this reason, a careful family history taking physical examination. The Reynolds Risk Score may reclassify their low-risk patients at higher risk individuals.

Persons moderate risk This group includes mostly middle-aged people. The Framingham Risk Score shows 10-19% chance of cardiovascular disease over the next 10 years. However, a positive family history and high hsCRP (if available) can modify the level of risk. These people need to change my lifestyle for 3 months, but may then be necessary pharmacological lipid-lowering therapy in people with at least two major risk factors and levels of LDL-CHOL> 130 mg / dL. The administration of lipid-lowering therapy in people with levels of LDL-CHOL 100-129 mg / dL is recommended for people with multiple cardiometabolic risk factors (visceral obesity, prediabetes, hypertension, etc.). The increase of atheromatic index (> 5) and the presence of high (> 2 mg / L) levels of CRP (if available) are also indications for lipid lowering regardless of the levels of LDL-CHOL.

Major risk factors: age> 45 years (men),> 55 years (women), positive family history of premature cardiovascular disease [in the presence of major vascular events in first degree relatives <55 years (men), <65 years (women)], hypertension , HDL-CHOL <40 mg / dL, smoking.

Individuals at high risk The Framingham Risk Score shows> 20% chance of cardiovascular disease over the next 10 years. At-risk individuals include:

A. Individuals with documented atherosclerotic disease (coronary artery disease, stroke, a significant degree of carotid stenosis, peripheral arterial disease, intermittent claudication, or aneurysm of the abdominal aorta).

B. All type II diabetic patients and patients with type I diabetes individuals older than 40 years.

C. People with chronic kidney disease with glomerular filtration (GFR) <60 mL/min/1, 73 m2.

In these individuals need intensive lifestyle modification and direct administration lipid lowering medication such as statins.

According to the above that one epidemiological study nature that has the purpose of observing and recording the progress of patients after their exit from a cardiology clinic or hospital unit because the acid after a cardiovascular event has clinical relevance. Compliance with medical instructions, achieving treatment goals for lipids by the addition of atorvastatin and personalized medicine practice are open field study. So this will be the subject of this study in order to highlight the clinical significance of atorvastatin in achieving the objectives of lipids (mainly LDL-CHOL) in blood plasma of "sensitive" of this group of patients in the Greek population, as possible representative (qualitatively and quantitatively)sample.

Dyslipidemia

The lipids of the human body is cholesterol (useful for the synthesis of cell membranes, hormones adrenal and gonads, and is a component of bile, the liver secretes) and triglycerides (serve as fuel and energy storage in adipose tissue ). The dyslipidemias are disorders (quantitative or qualitative) of the metabolism of lipoprotein particles (LDL, chylomicrons, HDL, VLDL) that transport lipids in the body.

Categories dyslipidemias - Primary dyslipidemias

The most significant primary lipid disorders are:

  1. Chylomicronemia (congenital or acquired): ↑ TRG → risk of acute pancreatitis.
  2. Familial Hypercholesterolemia a Homozygous (1/1.000.000 people): ↑ LDL CHOL b heterozygous (1/500 people): ↑ LDL CHOL.
  3. Mixed hyperlipidaemia Familial mixed (1/300 people): ↑ LDL-CHOL, ↑ TRG, ↓ HDL-CHOL.
  4. Familial hypertriglyceridemia (1/2.000 people): ↑ TRG.
  5. Familial decrease in HDL CHOL: ↓ HDL CHOL. Typically in patients with primary dyslipidemia needed medication. - Secondary dyslipidemias

In patients with abnormal lipid parameters of must exclude secondary dyslipidemias, ie disorders of lipid metabolism caused by diseases or drugs:

  1. Diabetes
  2. Hypothyroidism
  3. Obstructive liver disease
  4. Chronic kidney disease nephrotic syndrome-
  5. Obesity
  6. Alcohol abuse
  7. Medications that cause dyslipidemia a progestin b Anabolic Steroids c Corticosteroids D. Diuretics in large doses e b-blockers f Antiretroviral Drugs Interferon g h. Retinoids Estrogen i tamoxifen. In patients with secondary dyslipidemia required treatment of primary disease. Determination cohort for screening (Table 1)

    • Men over 40 and post-menopausal women
    • People with atherosclerotic disease regardless of age or clinical findings suggestive of dyslipidemia
    • Patients with diabetes regardless of age
    • Patients with chronic kidney disease (eGFR <60 mL/min/1, 73 m2 or the presence of albuminuria)
    • People with a family history of premature coronary heart disease
    • People with hypertension
    • People with chronic inflammatory diseases (lupus erythematosus, rheumatoid arthritis, psoriasis or acquired immunodeficiency syndrome)
    • Adults who smoke
    • adult with sexual dysfunction
    • Overweight and obese subjects with BMI> 27 kg/m2
    • Relatives of people with inherited lipid disorders
    • Children with a family history of hyperlipidemia or cardiovascular disease or other risk factors.

Statins - Atorvastatin

The cornerstone of treatment of dyslipidemia are statins.

Before initiation of lipid lowering requires the identification of lipid parameters {total cholesterol, triglycerides, HDL cholesterol and calculated LDL cholesterol [from the equation LDL-CHOL = total cholesterol - (triglycerides / 5 + HDL cholesterol)]} after fasting 12 - 14 hours, while the determination of glucose levels of TSH (to exclude underlying hypothyroidism) and transaminases (AST / ALT) and CPK to control the undesirable effects. Repeat determination of these parameters in patients who achieved their goals of treatment 2 times a year or when changing the therapeutic regimen. Repeat laboratory tests (lipid control effectiveness and liver enzymes and CPK for security control) after 12 weeks: a reason to discontinue treatment if ALT> 3 times the upper normal range or CPK> 5 times the upper normal range or in patients with myalgias. It should be noted that not necessitate interruption of treatment with statins or deferral of treatment in individuals with small increases in transaminases or CPK, while in these patients should be seeking other underlying causes of elevated liver and muscle enzymes. The choice of drug and dosage depend on the percentage change in HDL-CHOL necessary to achieve the objectives. Statins are usually the evening before bedtime the night. The lipid-lowering therapy is therapy for life, and most importantly, the patient adherence to treatment. It should be noted that doubling the dose of a statin results in additional reduction of HDL-CHOL (LDL) cholesterol by 6%.

The main goal of treatment is to reduce HDL-CHOL

The non HDL-CHOL (= T-CHOL - HDL-CHOL), proposed as a secondary target of lipid lowering mainly in people with high triglycerides. The target for the non HDL-CHOL is 30 mg / dL higher than the target for the HDL-CHOL. The decrease in triglycerides (<150 mg / dL) and increased HDL-CHOL (> 40 mg / dL for men and> 50 mg / dL for women) is considered desirable targets mainly lipid lowering in diabetic patients and in patients with cardiometabolic risk factors. Has also been suggested as a target of treatment to reduce the atheromatous index (T-CHOL/HDL-CHOL <4).

Atorvastatin is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides in adults, adolescents and children aged 10 years and older with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia combined (mixed) hyperlipidemia (type IIa and IIv by Fredrickson), when response to diet and other nonpharmacological measures is inadequate.

Atorvastatin is also indicated to reduce total cholesterol and LDL - cholesterol in adults with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg LDL apheresis) or if such treatments are unavailable.

Is also used to prevent cardiovascular events in adult patients who are thought to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. The triglycerides and cholesterol in the liver are incorporated into very low density lipoproteins (VLDL) and released into the plasma for delivery to peripheral tissues. The low density lipoprotein (LDL) is formed from VLDL and is catabolized primarily through receptor high affinity to LDL (LDL receptor).

Atorvastatin lowers cholesterol levels and lipoprotein plasma inhibiting HMG-CoA reductase and then the biosynthesis of cholesterol in the liver and increase the number of LDL receptors on the surface of liver cells which uptake and catabolism of LDL. Atorvastatin reduces LDL production and the number of particles of LDL. H atorvastatin causes profound and sustained increase of LDL receptor activity, in combination with a beneficial change in the quality of the circulating particles of LDL. Atorvastatin effectively reduces LDL-C in patients with homozygous familial hypercholesterolemia, a group of patients who do not usually respond to lipid-lowering medicines.

Atorvastatin in a dose-response study, was shown to reduce the concentration of T-CHOL (30% - 46%), the LDL-CHOL (41% - 61%), apolipoprotein B (34% - 50%) and triglycerides (14% - 33%) while producing variable increases HDL-CHOL and apolipoprotein A1. These results are so consistent in patients with heterozygous familial hypercholesterolaemia, non-familial forms of hypercholesterolemia and mixed hyperlipidemia, including patients with noninsulin-dependent diabetes mellitus.

It has been found that the decrease of the values ​​of total cholesterol, LDL-CHOL and apolipoprotein B reduces the risk of cardiovascular events and mortality thereof.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients on atorvastatin treatment after hospitalization due to cardiovascular events

Criteria

Inclusion Criteria:

  • Outpatients (External Ambulatory) Patients.
  • Male or female patients
  • 18 to 99 years
  • Patients with Hypercholesterolemia
  • Patients with and without treatment with statin
  • Patients enrolled in any of the study sites with acute cardiovascular event
  • Patients discharged with study medication (Antorcin ®)
  • Patients who have agreed and signed the consent form for the recording and processing of their personal data.

Exclusion Criteria:

  • Patients under 18 and over 99 years.
  • Women in pregnancy or lactation period
  • Patients enrolled in any of the study sites for any reason other than an acute cardiovascular event
  • Patients who discharged and take another statin drug formulation other than the study drug formulation (Antorcin ®)
  • Patients who have not consented and signed the consent form for the recording and processing of their personal data.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01770210

Contacts
Contact: Emmanouel Vavouranakis, FESC, FACC, FSCAI 30 213 2088678 mvav@hippocratio.gr

Locations
Greece
Rio University Hospital Active, not recruiting
Patras, Achaia, Greece
Evagelismos General State Hospital Recruiting
Athens, Attica, Greece
Sub-Investigator: Ilias Zarkos, MD         
Sub-Investigator: Dimitrios Vlachos, MD         
Euroclinic Private Hospital Recruiting
Athens, Attica, Greece
Sub-Investigator: Georgios Goumas, MD         
Gennimatas General State Hospital Recruiting
Athens, Attica, Greece
Sub-Investigator: Nikolaos Anatoliotakis, MD         
Konstantopoulio General Hospital Recruiting
Nea Ionia, Attica, Greece
Sub-Investigator: Stavros Spanodimos, MD         
General State Hospital Recruiting
Polygyros, Chalkidiki, Greece
Sub-Investigator: Paris Sofis, MD         
University Hospital Active, not recruiting
Heraklion, Crete, Greece
General State Hospital Active, not recruiting
Rhodes, Dodecanese, Greece
General State Hospital Active, not recruiting
Kalamata, Messinia, Greece
General State Hospital Recruiting
Edesssa, Pella, Greece
Sub-Investigator: Eleni Karapatsoudi, MD         
University Hospital Active, not recruiting
Larisa, Thessaly, Greece
Sismanogleio General State Hospital Active, not recruiting
Athens, Greece
Hippokration General Hospital Recruiting
Athens, Greece
Sub-Investigator: Ioannis Skiadas, MD         
General State Hospital Recruiting
Nikaia Piraeus, Greece
Sub-Investigator: Konstantinos Kostopoulos, MD         
Sub-Investigator: Filippos Filippou, MD         
Tzannion General State Hospital Recruiting
Piraeus, Greece
Sub-Investigator: Konstantinos Eglezopoulos, MD         
Papageorgiou Hospital Recruiting
Thessaloniki, Greece
Sub-Investigator: Ilias Zarvalis, MD         
424 Military Hospital Recruiting
Thessaloniki, Greece
Sub-Investigator: Dimitrios Eleftheriadis, MD         
Sponsors and Collaborators
Elpen Pharmaceutical Co. Inc.
Investigators
Principal Investigator: Antonis Ziakas, Ass Professor AHEPA hospital of Thessaloniki, Greece
Principal Investigator: Charalampos Karvounis, Professor AHEPA hospital of Thessaloniki, Greece
Principal Investigator: Georgios Maligos, Registrat A Papanikolaou hospital of Thessaloniki, Greece
Principal Investigator: Ioannis Kanonidis, Professor Hippokration hospital of Thessaloniki, Greece
Principal Investigator: Dimitrios Psyropoulos, Director Gennimatas hospital of Thessaloniki, Greece
Principal Investigator: Ioannis Vogiatzis, Director Hospital of Veria, Greece
Principal Investigator: Pantelis Kligatsis, Director Hospital of Florina, Greece
Principal Investigator: David Symeonidis, Director Hospital of Kavala, Greece
Principal Investigator: Nikolaos Theodoridis, Director Hospital of Drama, Greece
Principal Investigator: Stylianos Lampropoulos, Director Hospital of Ptolemaida, Greece
Principal Investigator: Georgios Spyromitros, Director Hospital of Katerini, Greece
Principal Investigator: Ioannis Tsounos, Director Agios Pavlos hospital of Thessaloniki, Greece
Principal Investigator: Vlasis Pyrgakis, Director George Gennimatas hospital of Athens, Greece
Principal Investigator: Andreas Tsellios, Registrat NIMTS hospital of Athens, Greece
Principal Investigator: Ioannis Kalikazaros, Director Hippokration hospital of Athens, Greece
Principal Investigator: Dimitrios Richter, Director Euroclinic of Athens, Greece
Principal Investigator: Emmanouel Kallieris, Associate Director Metropolitan hospital of Piraeus, Greece
Principal Investigator: Apostolos Katsivas, Director Red Cross Hospital of Athens, Greece
Principal Investigator: Stefanos Foussas, Director Tzannion hospital of Piraeus, Greece
Principal Investigator: Dimitrios Tziakas, Ass. Professor University Hospital of Alexandroupolis, Greece
Principal Investigator: Konstantinos Papaioannou, Director Hospital of Polygyros, Greece
Principal Investigator: Ioannis Styliadis, Director Papageorgiou Hospital of Thessaloniki, Greece
Principal Investigator: Pantelis Makridis, Director Hospital of Edessa, Greece
Principal Investigator: Panayotis Kyriakidis, Director 424 military hospital of Thessaloniki, Greece
Principal Investigator: Georgios Karakostas, Director Hospital of Kilkis, Greece
Principal Investigator: Vasilios Vasilikos, Ass Professor Hippokration hospital of Thessaloniki, Greece
Principal Investigator: Sotirios Patsilinakos, Director Konstantopoulio General Hospital of Athens
Principal Investigator: Dimitrios Sionis, Director Sismanogleio General Hospital of Athens
Principal Investigator: Antonios Sideris, Director Evagelismos General Hospital of Athens
Principal Investigator: Athanasios Manolis, Director Asklepiion General Hospital of Voula
Principal Investigator: Chrysostomos Oikonomou, Director Laikon General Hospital of Athens
Principal Investigator: Panagiotis Pentzeridis, Director General State Hospital of Nikaia, Piraeus
Principal Investigator: Athanasios Pras, Director General State Hospital of Chania, Crete
Principal Investigator: Alkiviadis Dermitzakis, Director Venizeleio General State Hospital of Heraklion, Crete
Principal Investigator: Panagiotis Vardas, Professor University Hospital of Heraklion, Crete
Principal Investigator: Dimitrios Alexopoulos, Professor Rio University Hospital of Patras
Principal Investigator: Andreas Mazarakis, Director Agios Andreas General State Hospital of Patras
Principal Investigator: Antonios Draganigos, Director General State Hospital of Corfu
Principal Investigator: Filippos Tryposkiadis, Professor University Hospital of Larisa, Thessaly
Principal Investigator: Spyridon Zombolos, Director General State Hospital of Kalamata
Principal Investigator: Dimitrios Platogiannis, Director General State Hospital of Trikala
Principal Investigator: Panagiotis Stasinos, Director General State Hospital of Ierapetra, Crete
Principal Investigator: Nikitas Moschos, Director General State Hospital of Rhodes
Principal Investigator: Chrysostomos Dilanas, Director General State Hospital of Korinthos
  More Information

Publications:
Guidelines of the Hellenic Society of Atherosclerosis for the diagnosis and treatment of dyslipidemia M. Elisaf, Ch. Pitsavos, E. Liberopoulos, V. Athyros Hellenic Journal of Atherosclerosis 2(3):163-168, 06/04/2011

Responsible Party: Elpen Pharmaceutical Co. Inc.
ClinicalTrials.gov Identifier: NCT01770210     History of Changes
Other Study ID Numbers: 2012-ATR-EL-34
Study First Received: January 14, 2013
Last Updated: January 30, 2014
Health Authority: Greece: National Organization of Medicines

Keywords provided by Elpen Pharmaceutical Co. Inc.:
hypercholesterolemia
atorvastatin
cardiovascular events

Additional relevant MeSH terms:
Cardiovascular Diseases
Atorvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 01, 2014